GlucoTrack (NASDAQ:GCTK) Stock Falls 5.9% – Should You Sell?

Shares of GlucoTrack, Inc. (NASDAQ:GCTK) dropped 5.9% during mid-day trading on Tuesday. The stock traded as low as $0.30 and last traded at $0.32. Approximately 28,504 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 707,506 shares. The stock had previously closed at $0.34.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, GlucoTrack currently has an average rating of “Sell”.

GlucoTrack Trading Down 20.0%

The stock has a market cap of $284,160.00, a P/E ratio of -0.00 and a beta of 0.90. The company’s 50 day moving average price is $2.69 and its two-hundred day moving average price is $19.20.

GlucoTrack Company Profile

GlucoTrack, Inc. (NASDAQ:GCTK) is a medical-device company focused on developing glucose-monitoring technologies for people with diabetes. The company’s work is aimed at providing alternatives to conventional blood-glucose testing and commercially available continuous glucose-monitoring systems. GlucoTrack’s earlier product was the GlucoTrack device, a noninvasive glucose-monitoring system designed to estimate glucose levels through a sensor attached to the earlobe. The company has also been developing an implantable continuous blood glucose monitoring system intended to provide ongoing glucose measurements over an extended period.